NasdaqGS:CALA

Stock Analysis Report

Executive Summary

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States.

Snowflake

Fundamentals

Flawless balance sheet and fair value.

Risks

  • Calithera Biosciences has significant price volatility in the past 3 months.

Share Price & News

How has Calithera Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.6%

NasdaqGS:CALA

0.2%

US Biotechs

0.2%

US Market


1 Year Return

-16.4%

NasdaqGS:CALA

-9.1%

US Biotechs

-0.7%

US Market

CALA underperformed the Biotechs industry which returned -7.3% over the past year.

CALA underperformed the Market in United States of America which returned 0.3% over the past year.


Share holder returns

CALAIndustryMarket
7 Day2.6%0.2%0.2%
30 Day-4.1%0.9%-2.7%
90 Day-30.6%2.4%1.6%
1 Year-16.4%-16.4%-8.4%-9.1%1.6%-0.7%
3 Year26.4%26.4%8.3%4.6%40.0%30.9%
5 Yearn/a4.5%-0.3%53.8%36.8%

Price Volatility Vs. Market

How volatile is Calithera Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Calithera Biosciences undervalued based on future cash flows and its price relative to the stock market?

48%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Calithera Biosciences's share price is below the future cash flow value, and at a moderate discount (> 20%).

Calithera Biosciences's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Calithera Biosciences is loss making, we can't compare its value to the US Biotechs industry average.

Calithera Biosciences is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Calithera Biosciences, we can't assess if its growth is good value.


Price Based on Value of Assets

Calithera Biosciences is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Calithera Biosciences expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

5.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Calithera Biosciences's revenue is expected to grow significantly at over 20% yearly.

Calithera Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.

Calithera Biosciences's revenue growth is expected to exceed the United States of America market average.

Unable to compare Calithera Biosciences's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Calithera Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Calithera Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Calithera Biosciences performed over the past 5 years?

-21.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Calithera Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Calithera Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Calithera Biosciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Calithera Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Calithera Biosciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Calithera Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Calithera Biosciences's financial position?


Financial Position Analysis

Calithera Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Calithera Biosciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Calithera Biosciences has no debt.

Calithera Biosciences has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Calithera Biosciences has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Calithera Biosciences has sufficient cash runway for 2.1 years based on current free cash flow.

Calithera Biosciences has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 54.6% each year.


Next Steps

Dividend

What is Calithera Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Calithera Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Calithera Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Calithera Biosciences has not reported any payouts.

Unable to verify if Calithera Biosciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Calithera Biosciences has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Calithera Biosciences's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Calithera Biosciences's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Susan Molineaux (65yo)

9.4yrs

Tenure

US$2,033,057

Compensation

Dr. Susan M. Molineaux, Ph.D., Co-founded Calithera Biosciences, Inc. in June 2010 and has been its Chief Executive Officer and President since June 2010. Dr. Molineaux also serves as Principal Financial O ...


CEO Compensation Analysis

Susan's remuneration is higher than average for companies of similar size in United States of America.

Susan's compensation has increased whilst company is loss making.


Management Age and Tenure

3.0yrs

Average Tenure

48yo

Average Age

The tenure for the Calithera Biosciences management team is about average.


Board Age and Tenure

4.3yrs

Average Tenure

55.5yo

Average Age

The tenure for the Calithera Biosciences board of directors is about average.


Insider Trading

More shares have been bought than sold by Calithera Biosciences individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$200,20827 Jun 19
Susan Molineaux
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares51,600
Max PriceUS$3.88

Ownership Breakdown


Management Team

  • Susan Molineaux (65yo)

    Co-Founder

    • Tenure: 9.4yrs
    • Compensation: US$2.03m
  • Christopher Molineaux (66yo)

    Senior Vice President of Development

    • Tenure: 6.3yrs
    • Compensation: US$446.60k
  • Eric Sjogren (62yo)

    Senior Vice President of Drug Discovery

    • Tenure: 9.2yrs
    • Compensation: US$959.51k
  • Stephanie Wong (45yo)

    Senior VP of Finance & Secretary

    • Tenure: 0.0yrs
  • Sumita Ray (45yo)

    Senior VP

    • Tenure: 1.8yrs
    • Compensation: US$1.26m
  • Hagit Glickman

    Head of People & Culture

    • Tenure: 0.0yrs
  • Curtis Hecht (48yo)

    Chief Business Officer

    • Tenure: 0.6yrs
    • Compensation: US$883.44k
  • Keith Orford (47yo)

    Chief Medical Officer

    • Tenure: 3.3yrs
    • Compensation: US$1.14m
  • Jennifer McNealey

    Vice President of Investor Relations & Strategy

    • Tenure: 2.7yrs
  • Sam Whiting

    Senior Vice President of Clinical Development

    • Tenure: 0.6yrs

Board Members

  • Jean George (61yo)

    Director

    • Tenure: 6.9yrs
    • Compensation: US$98.30k
  • Henry Wolff (70yo)

    Director

    • Tenure: 4.7yrs
    • Compensation: US$97.30k
  • Deepa Pakianathan (54yo)

    Lead Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$120.30k
  • Susan Molineaux (65yo)

    Co-Founder

    • Tenure: 9.4yrs
    • Compensation: US$2.03m
  • John Drachman (57yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: US$87.30k
  • Sunil Agarwal (49yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$93.80k
  • Suzy Jones (53yo)

    Director

    • Tenure: 3.0yrs
    • Compensation: US$89.80k
  • Blake Wise (48yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$86.05k

Company Information

Calithera Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Calithera Biosciences, Inc.
  • Ticker: CALA
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$213.486m
  • Shares outstanding: 53.77m
  • Website: https://www.calithera.com

Number of Employees


Location

  • Calithera Biosciences, Inc.
  • 343 Oyster Point Boulevard
  • Suite 200
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CALANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2014
2CBDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014

Biography

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 00:55
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.